mercaptopurine and Adenocarcinoma

It has been proposed that effective disease control through abrogation of inflammation in IBD may also reduce CRC risk in these individual patients. This article summarizes the potential for medical therapy to reduce the risk of CRC via primary and secondary prevention, and offers practical ways in which a goal of mucosal improvement or healing may be incorporated into clinical practice.

Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Intestinal Mucosa; Mercaptopurine; Mesalamine; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclophosphamide; Cytarabine; Female; Fluorouracil; Humans; Leukemia L1210; Leukemia, Lymphoid; Lymphoma; Melphalan; Mercaptopurine; Methotrexate; Mice; Multiple Myeloma; Neoplasms; Nitrogen Mustard Compounds; Prednisone; Pregnancy; Time Factors; Trophoblastic Neoplasms; Vinblastine

Topics: Adenocarcinoma; Anemia; Bone Marrow Diseases; Carcinoma, Squamous Cell; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colonic Neoplasms; Humans; Leukopenia; Lung Neoplasms; Mercaptopurine; Nausea; Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Thrombocytopenia; Vomiting

Immunosuppressant medications for Inflammatory Bowel Disease can help with both symptoms and disease progression. However, like immunosuppressants used in transplant patients, they are now suspect of contributing to nonmelenoma skin cancer (NMSC). Presented is a case of a 57-year-old Jewish man with Crohn's Disease who was diagnosed with a total of 84 NMSCs. We hope to elucidate the risk of immunosuppressants, particularly the thiopurines, on the development of NMSC.

Topics: Adenocarcinoma; Crohn Disease; Fatal Outcome; Hawaii; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Male; Mercaptopurine; Middle Aged; Skin Neoplasms; Sunlight

Pancreatic adenocarcinoma is one of the malignancies that is highly resistant to therapy and among the leading causes of cancer-related death. Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance. Members of this family's C-branch, also referred to as multidrug resistance-associated proteins (MRPs), might be of particular interest because they are able to efflux nucleoside analogs used in the treatment of pancreatic cancer. Expression of MRP1, MRP3, MRP4, and MRP5 in human pancreas and pancreatic carcinoma has been reported. However, contributions of MRPs to chemoresistance of pancreatic cancer are not fully understood. MRP5 mRNA expression in pancreatic adenocarcinoma cell lines correlated significantly with cellular sensitivity to 5-fluorouracil (5-FU) (r = 0.738, p < 0.05). Long-term treatment with 5-FU increased expression of MRP5 by 2.4-fold and was associated with significant drug resistance [IC(50) values for control and 5-fluorouracil (5-FU)-resistant Patu-T cell lines were 11.3 ± 5.3 and 33.2 ± 6.9 μM, respectively (p < 0.05)]. Consequently, overexpression of MRP5 in Colo-357 cells resulted in significantly reduced accumulation of 5-FU related radioactivity and 5-FU cytotoxicity. Knockdown of MRP5 significantly increased cellular cytotoxicity of 5-FU to Patu-02 cells and enhanced accumulation of radioactivity related to 5-FU and its metabolites. Our results suggest that MRP5 is expressed and functionally active and contributes to variable sensitivities of pancreatic adenocarcinoma cell lines to 5-FU. Further investigations using models that resemble human pancreas tumors are necessary to prove a causative relation between expression and activity of MRP5 and tumor resistance to 5-FU.

Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gene Knockdown Techniques; Humans; Multidrug Resistance-Associated Proteins; Pancreas; Pancreatic Neoplasms; RNA; RNA Interference; Tumor Cells, Cultured

Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin

Angiogenesis has been identified as an important target for antineoplastic therapy. The use of purine analogue antimetabolites in combination chemotherapy of solid tumors has been proposed. To assess the possibility that selected purine analogues may affect tumor neovascularization, 6-methylmercaptopurine riboside (6-MMPR), 6-methylmercaptopurine, 2-aminopurine, and adenosine were evaluated for the capacity to inhibit angiogenesis in vitro and in vivo. 6-MMPR inhibited fibroblast growth factor-2 (FGF2)-induced proliferation and delayed the repair of mechanically wounded monolayer in endothelial GM 7373 cell cultures. 6-MMPR also inhibited the formation of solid sprouts within fibrin gel by FGF2-treated murine brain microvascular endothelial cells and the formation of capillary-like structures on Matrigel by murine aortic endothelial cells transfected with FGF2 cDNA. 6-MMPR affected FGF2-induced intracellular signaling in murine aortic endothelial cells by inhibiting the phosphorylation of extracellular signal-regulated kinase-2. The other molecules were ineffective in all of the assays. In vivo, 6-MMPR inhibited vascularization in the chick embryo chorioallantoic membrane and prevented blood vessel formation induced by human endometrial adenocarcinoma specimens grafted onto the chorioallantoic membrane. Also, topical administration of 6-MMPR caused the regression of newly formed blood vessels in the rabbit cornea. Thus, 6-MMPR specifically inhibits both the early and the late phases of the angiogenesis process in vitro and exerts a potent anti-angiogenic activity in vivo. These results provide a new rationale for the use of selected purine analogues in combination therapy of solid cancer.

Topics: 2-Aminopurine; Adenocarcinoma; Adenosine; Allantois; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aorta; Brain; Calcium-Calmodulin-Dependent Protein Kinases; Cattle; Cells, Cultured; Chick Embryo; Chorion; Cornea; Depression, Chemical; Endometrial Neoplasms; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Humans; Mercaptopurine; Methylthioinosine; Mice; Mitogen-Activated Protein Kinase 1; Neoplasm Transplantation; Neovascularization, Physiologic; Phosphorylation; Protein Processing, Post-Translational; Rabbits; Recombinant Fusion Proteins; Signal Transduction; Transfection

We investigated possible mechanisms of the antitumor action of gamma-(9H-purine-6-yl) thiomethyl L-glutamate (6-MPG), a water-soluble derivative of 6-MP. In the double grafted tumor system, BALB/c mice were inoculated intradermally with 10(6) cells of MethA fibrosarcoma at the right inguinal region on day 0 (the primary tumor) and later with 3 x 10(6) cells at the left on day 10 (the secondary tumor). Intraperitoneal administration of 6-MPG at a dose of 100 mg/kg/day from day 3 through 7 completely prevented growth of the secondary tumor. 6-MPG showed no effect on growth of colon 26 adenocarcinoma cells inoculated in place of the secondary MethA cells (antigen specificity). 6-MPG did not inhibit the secondary MethA growth in the BALB/c (nu/nu) mouse. The inhibitory effect of 6-MPG on the secondary tumor growth was diminished by prior treatment of the primed animals with cyclosporin A and anti-Thy antibody. Spleen cells from the tumor-bearing mice treated with 6-MPG showed a tumor-neutralizing activity (Winn assay). Treatment of the spleen cells with anti-CD8 antibody plus complement diminished the tumor-neutralizing effect but that with anti-CD4 antibody plus complement did not, indicating that CD8-positive cells are responsible for potentiation of the tumor immunity. These results suggest that the antitumor effect of 6-MPG against the secondary tumor is elicited by augmenting tumor specific T-cell production.

Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Cyclosporine; Drug Interactions; Fibrosarcoma; Immunosuppressive Agents; Male; Mercaptopurine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phenotype; Solubility; Spleen; T-Lymphocytes; Water

Both intact mice and those with transplantable adenocarcinoma 755 were used in the investigation. The nitroxyl radical Tempol was shown to cut down the toxicity of 6-mercaptopurine and potentiate its antitumor effect to a certain degree. The study results suggest on the basis of an investigation of cytochrome P450 and some other evidence that said effect of Tempol might be due, at least, in part to antioxidant activity.

Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antioxidants; Cyclic N-Oxides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Male; Mercaptopurine; Mice; Mice, Inbred C57BL; Spin Labels; Survival Analysis

Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Daunorubicin; Humans; Ileal Neoplasms; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Thioguanine

Peculiarities of growth and recurrences of the adenocarcinoma 755 are studied in C57Bl/6 mice and hybrids (DBA/2 X +C57Bl/6)F1 after chemotherapy with cyclophosphamide and 6-mercaptopurine (6-MP). The growth rate of tumours was practically identical in the both mice strains. Growth rate of recurrences was slower in examined lines than in corresponding tumours. The obtained results showed that the antitumour effect of the drugs, in particularly of 6-MP, and the growth rate of the first and that of the second recurrences clearly depended on the tumour host strain.

Topics: Adenocarcinoma; Animals; Cyclophosphamide; Drug Evaluation, Preclinical; Female; Mercaptopurine; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Recurrence, Local; Neoplasm Transplantation; Time Factors

The two injections of cyclophosphane (100 mg/kg) to mice with adenocarcinoma 755 on the 6th and 11th days after tumour transplantation had no influence on the cell cycle but induced a decrease of its growth rate due to an increase in the level of cell losses. The third cyclophosphane injection (the same dose) on the 17th day after the tumour transplantation or an additional course of five 6-mercaptopurine injections (50 mg/kg each dose) did not change essentially the growth rate of tumours.

Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Mercaptopurine; Mice; Neoplasm Transplantation

Topics: Adenocarcinoma; Animals; Bone Marrow; Cell Division; Cell Line; Dose-Response Relationship, Drug; Drug Resistance; Humans; Leukemia L1210; Mercaptopurine; Mice; Structure-Activity Relationship; Thioinosine; Thionucleotides

Topics: Adenocarcinoma; Adolescent; Age Factors; Autopsy; Brain Neoplasms; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Mercaptopurine; Methotrexate; Neoplasms, Multiple Primary; Pancreas; Pancreatic Neoplasms; Prednisone; Vincristine

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aza Compounds; Azaguanine; Carcinoma, Squamous Cell; Cell Line; Cells, Cultured; Drug Resistance; Humans; Hypoxanthines; Imidazoles; Inosine; Leukemia L1210; Mercaptopurine; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pentosyltransferases; Phosphotransferases; Purines

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Dactinomycin; Fluorouracil; Melphalan; Mercaptopurine; Methylthiouracil; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Nitrogen Mustard Compounds; Rats; Sarcoma, Experimental; Time Factors

Topics: Adenocarcinoma; Animals; Antimetabolites; Glutathione; Immunosuppressive Agents; Mercaptopurine; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Purines

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Line; Cyclization; Cyclophosphamide; Cytarabine; Cytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Leukemia L1210; Leukemia, Experimental; Male; Mercaptopurine; Methotrexate; Mice; Mitomycins; Neoplasms, Experimental; Sarcoma 180

Topics: Adenocarcinoma; Amides; Animals; Antineoplastic Agents; Ascites; Female; Formates; Guinea Pigs; Injections, Intraperitoneal; Leukemia L1210; Leukemia, Experimental; Male; Mercaptopurine; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Nucleosides; Sarcoma, Experimental; Transplantation, Homologous

Topics: Adenocarcinoma; Animals; Chromatography, Paper; Electrophoresis; Glucosyltransferases; L Cells; Leukemia L1210; Liver Neoplasms; Mercaptopurine; Methylation; Mice; Neoplasms, Experimental; Nucleosides; Nucleotides; Purines; Sulfur Isotopes

Topics: Adenocarcinoma; Animals; Carcinoma 256, Walker; Chlorambucil; Cyclophosphamide; Melphalan; Mercaptopurine; Mice; Neoplasms, Experimental; Sarcoma, Experimental

Topics: Adenocarcinoma; Animals; Cell Nucleolus; Cell Nucleus; Cytoplasmic Granules; Endoplasmic Reticulum; Mercaptopurine; Mice; Microscopy, Electron; Mitochondria; Neoplasms, Experimental

Topics: Adenocarcinoma; Aged; Bone Marrow Diseases; Erythrocytes; Humans; Leukemia; Lung Neoplasms; Male; Megakaryocytes; Mercaptopurine; Middle Aged; Thiotepa; Thrombocythemia, Essential

Topics: ABO Blood-Group System; Absorption; Adenocarcinoma; Antineoplastic Agents; Blood Platelets; Breast Neoplasms; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Dysgerminoma; Erythrocytes; Female; Hemagglutination Tests; Humans; Immune Sera; Isoantigens; Leukemia; Leukocytes; Male; Mercaptopurine; Methotrexate; Nitrogen Mustard Compounds; Pregnancy; Uracil Mustard

Topics: Adenine; Adenocarcinoma; Buffers; Carbon Isotopes; Guanine; Hydrogen-Ion Concentration; Hypoxanthines; In Vitro Techniques; Kinetics; Mercaptopurine; Neoplasms, Experimental; Nucleotides; Purines; Thioguanine; Transferases

Topics: Adenine; Adenocarcinoma; Animals; Azaserine; Carbon Isotopes; Cell Line; Feedback; Hypoxanthines; Mercaptopurine; Methotrexate; Neoplasms, Experimental; Nucleotides; Phosphotransferases; Purines; Sarcoma 180; Thioguanine

Topics: Adenocarcinoma; Azoles; Binding Sites; Carbon Isotopes; Culture Techniques; Diphosphates; Female; Glutamine; Hot Temperature; Hydrogen-Ion Concentration; Kinetics; Magnesium; Mercaptopurine; Neoplasms, Experimental; Nucleotides; Quaternary Ammonium Compounds; Ribose; Sulfates; Transferases

Topics: Adenocarcinoma; Alkylating Agents; Animals; Antimetabolites; Cyclophosphamide; Mercaptopurine; Mice; Mitosis; Neoplasm Transplantation; Neoplasms, Experimental; Plasmacytoma; Sarcoma 180

Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamide; Dactinomycin; Female; Floxuridine; Fluorouracil; Hodgkin Disease; Humans; Melphalan; Mercaptopurine; Methotrexate; Nandrolone; Neoplasms; Nitrogen Mustard Compounds; Norethindrone; Prednisolone; Progesterone; Testosterone; Thiotepa; Uterine Neoplasms; Vinblastine

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chemical Phenomena; Chemistry; Leukemia L1210; Lipids; Mercaptopurine; Methods; Mice; Solubility

Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Drug Synergism; Humans; Lung Neoplasms; Mercaptopurine; Methotrexate; Mitomycins; Neoplasm Metastasis; Radiotherapy Dosage; Triaziquone

Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Drug Synergism; Female; Fluorouracil; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Vinblastine

Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Drug Synergism; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Mouth Neoplasms; Neoplasm Metastasis; Pharyngeal Neoplasms; Urogenital Neoplasms; Vinblastine

Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betamethasone; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lectins; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Pleural Neoplasms; Sarcoma; Vinblastine

Topics: Adenocarcinoma; Alkylation; Animals; Antimetabolites; Carcinoma, Ehrlich Tumor; Glutamine; Leukemia, Experimental; Leukemia, Radiation-Induced; Mammary Neoplasms, Experimental; Mercaptopurine; Mice; Neoplasm Transplantation; Sarcoma 180

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Culture Techniques; Flavonoids; Fluorouracil; HeLa Cells; Humans; Lung Neoplasms; Melphalan; Mercaptopurine; Methods; Mitomycins; Neoplasms; Rectal Neoplasms; Stomach Neoplasms

Topics: Adenocarcinoma; Adult; Aged; Anti-Bacterial Agents; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Leukemia, Myeloid; Lymphatic Metastasis; Mastectomy; Mercaptopurine; Methotrexate; Middle Aged

Topics: Adenocarcinoma; Animals; Chromatography, Paper; DNA, Neoplasm; Mercaptopurine; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Thioguanine

Topics: Adenocarcinoma; Antineoplastic Agents; Aspergillus; Azaserine; Carcinoma, Bronchogenic; Chick Embryo; Glycine; Mercaptopurine; Neoplasms; Neoplasms, Experimental; Puromycin; Pyrroles; Research; Saccharomyces; Tissue Culture Techniques; Triethylenemelamine

Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cortisone; Humans; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mercaptopurine; Mice; Neoplasms; Neoplasms, Experimental; Nitrogen Mustard Compounds; Pharmacology; Puromycin; Research; Sarcoma 180; Uracil Mustard; Zymosan

Topics: Adenocarcinoma; Blood Cell Count; Carcinoma, Renal Cell; Epoetin Alfa; Erythropoietin; Geriatrics; Humans; Kidney Neoplasms; Lung Neoplasms; Mercaptopurine; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Nephrectomy

Topics: Adenine Nucleotides; Adenocarcinoma; Adenosine Monophosphate; Antimetabolites; Cell-Free System; Inosine Monophosphate; Mercaptopurine; Mice; Neoplasms, Experimental; Nucleotides; Pharmacology; Research; Ribonucleotides; Tissue Culture Techniques

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carbonates; Chemistry, Pharmaceutical; Leukemia L1210; Mercaptopurine; Mice; Purines; Research; Sarcoma 180; Tissue Culture Techniques

Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Agents; Bence Jones Protein; Cecum; Cyclophosphamide; gamma-Globulins; Intestinal Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Mice; Multiple Myeloma; Neoplasms; Neoplasms, Experimental; Neoplasms, Plasma Cell; Pathology; Pharmacology; Prednisolone; Radiation Effects; Research

Topics: Adenocarcinoma; Antineoplastic Agents; Azaserine; Humans; In Vitro Techniques; Infrared Rays; Magnetic Resonance Spectroscopy; Mercaptopurine; Mitosporic Fungi; Spectrum Analysis; Ultraviolet Rays

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Mercaptopurine; Mice; Neoplasms; Neoplasms, Experimental; Research; Sarcoma 180; Thioguanine; Toxicology

Topics: Adenocarcinoma; Animals; Breast; Intestinal Neoplasms; Mercaptopurine; Mice

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Mercaptopurine; Mice; Pharmacology; Research

Topics: Adenocarcinoma; Antimetabolites; Antineoplastic Agents; Chemical Phenomena; Chemistry; Mercaptopurine; Pharmacology; Purines; Research; Sulfhydryl Compounds; Thioguanine